A pharmacist-led collaborative drug therapy management program at NYC Health + Hospitals/Bellevue reported high patient satisfaction, and every surveyed patient said they felt respected and supported by their pharmacist.
|Articles|July 29, 2022
- July 2022
- Volume 88
- Issue 7
Pet Peeves: July 2022
Brought to you by The Sassy Pharmacist
Advertisement
Shrouded in Mystery
After you ring out the prescriptions and give to the patient they ask “so what did I get here?”
DIY
Patients who ask the pharmacist to go online to schedule a COVID-19 test or vaccine for them.
Not a Refill Request
The pharmacist sends the physician the prior authorization rejection and then gets a script for the same thing.
What’s Bothering You?
Bossy patients, abandoned prescriptions, drive-through demands? We want to know! Send your pet peeves to cmollison@pharmacytimes.com. We’ll share them here and online.
Articles in this issue
about 4 years ago
National Practitioner Data Bank Aims to Reduce Malpracticeabout 4 years ago
July 2022: Generic Product Newsabout 4 years ago
Pharmacists Can Help Manage Patients With Parkinson Diseaseabout 4 years ago
Quviviq From Idorsia Pharmaceuticalsabout 4 years ago
OTC Case Studies: Rhinitisabout 4 years ago
July 2022: Rx Product Newsabout 4 years ago
Know Your Salary Rangeabout 4 years ago
Help Patients Use Inhalers Properlyabout 4 years ago
Illinois Legislature Empowers Pharmacistsabout 4 years ago
Board’s Licensure Revocations Are Upheld on AppealAdvertisement
Related to this article
A Novo Nordisk-funded claims analysis of adults with type 2 diabetes found an adjusted HR of 1.06 for MACE with switching, though the findings cannot show causation.
Invasive pneumococcal disease may be the first sign of undiagnosed blood cancers and antibody deficiencies in adults, a new study finds.
A new analysis finds a significant weight loss edge for tirzepatide under one estimand but not another; no head-to-head trial exists at these doses.
In SCOUT-HCM, mavacamten reduced the Valsalva LVOT gradient by 48 mm Hg versus placebo in adolescents. REMS, echo monitoring, and CYP interactions still apply in the new population.
Indirect comparison links orforglipron 17.2 mg to 1.5% more weight loss and 0.3% more A1C lowering than oral semaglutide 25 mg in adults with type 2 diabetes.
Pharmacists can help overcome influenza vaccine hesitancy by correcting common misconceptions, routinely asking every patient about vaccination, and leveraging their standing as trusted health care professionals.
Phase 3 TRIUMPH-2 data presented at EASD show HbA1C reductions up to 1.6%, with GI effects, hypotension, and dysesthesia as key counseling points.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Tirzepatide Linked to More Weight Loss Than Semaglutide 7.2 mg
2
Pharmacist, Advocate, Ally: Delivering Comprehensive Gender-Affirming Care
3
Semaglutide 2 mg Tied to Lower MACE Risk Than Tirzepatide Switch
4
Statin Myths: Why Patients Avoid Cholesterol-Lowering Therapy
5